Drug duo shows promise in Tough-to-Treat cancers
Disease control
Completed
This study tested a combination of two drugs, telatinib and Keytruda, in 16 people with advanced stomach, gastroesophageal junction, or liver cancer. The goal was to see if the combo could slow cancer growth or improve survival. Participants had already tried other treatments wit…
Phase: PHASE2 • Sponsor: Andrew Hendifar, MD • Aim: Disease control
Last updated May 01, 2026 15:59 UTC